Innocan Pharma Reports Promising Q1 2025 Results with Revenue Growth and Strategic Developments Innocan Pharma Corporation announces significant revenue growth of 15% in Q1 2025, alongside innovative developments in drug delivery technology and expanded markets.

Innocan Pharma Reports Promising Q1 2025 Results with Revenue Growth and Strategic Developments #USA #Innocan_Pharma #LPT-CBD #Herzliya #BI_Sky_Global

Innocan Pharma Achieves Record Revenue Growth in 2024 with Expansion in Product Offerings Innocan Pharma reports an impressive revenue growth for 2024, reaching $29.4 million, driven by strong demand and innovative products in the wellness sector.

Innocan Pharma Achieves Record Revenue Growth in 2024 with Expansion in Product Offerings #Canada #Calgary #Innocan_Pharma #BI_Sky_Global #CBD_Products

Innocan Pharma's BI Sky Global Achieves HRIPT Testing Completion and Daily Sales Milestone Innocan Pharma's subsidiary BI Sky Global has completed crucial HRIPT testing and reached a remarkable sales target of 5,000 units daily in 2024.

Innocan Pharma's BI Sky Global Achieves HRIPT Testing Completion and Daily Sales Milestone #USA #Calgary #Innocan_Pharma #BI_Sky_Global #HRIPT_Testing